1. Hims & Hers presents a strong 'Buy' opportunity after a 30% price drop, despite growth concerns and insider selling; 2. The company targets $6.5B revenue and $1.3B+ adjusted EBITDA by FY30, signaling a 4x profit expansion; 3. Attractive valuations (32.8x EV/FY25 EBITDA) and expansion into hormone health/longevity markets support long-term growth.